Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBFB | Q13951 | 6/20 | 0.45 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CCND3 | P30281 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26051103 | 0.87 | CBFB (0.41) | CBFBRUNX1ATRKDM4EALDH1A1 | |
| SCHEMBL19228823 | 0.84 | RUNX1 (0.46) | CBFBRUNX1ALOX5EPHX2KDM4E | |
| SCHEMBL19228808 | 0.82 | RUNX1 (0.57) | RUNX1ATRACHESMN1; SMN2 | |
| SCHEMBL19228814 | 0.81 | ACHE (0.56) | RUNX1ACHESMN1; SMN2 | |
| SCHEMBL19228806 | 0.80 | RUNX1 (0.55) | RUNX1ACHE | |
| SCHEMBL19228805 | 0.80 | RUNX1 (0.68) | RUNX1ALDH1A1ACHE | |
| SCHEMBL19228807 | 0.79 | RUNX1 (0.52) | RUNX1KDM4EALDH1A1POLBACHE | |
| SCHEMBL19228812 | 0.78 | RUNX1 (0.56) | CBFBRUNX1ATRALDH1A1NPC1 | |
| SCHEMBL19228815 | 0.77 | RUNX1 (0.55) | RUNX1KDM4EALDH1A1MAPTHPGD | |
| SCHEMBL19228809 | 0.74 | CBFB (0.49) | CBFBRUNX1CDK4CCNA2CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233375-A1 | CANCER THERAPEUTICS | RUNX1, CBFB, MCL1 | CBFB 2/4885RUNX1 1/4885CDK4 1728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.